keyword
https://read.qxmd.com/read/38148518/therapeutic-frameworks-in-integration-sessions-in-substance-assisted-psychotherapy-a-systematised-review
#21
REVIEW
Sascha B Thal, Paris Baker, Jonathon Marinis, Michelle Wieberneit, Jason M Sharbanee, Raimundo Bruno, Petra M Skeffington, Stephen J Bright
Serotonergic psychedelics and related substances have been explored as potential adjuncts in substance-assisted psychotherapy (SAPT) for treating various disorders. SAPT can be divided into three phases: preparation, administration and integration. Integration is commonly defined as the comprehension and effective application of insights from psychedelic experiences into everyday life. However, there is limited research regarding the most appropriate therapeutic approach during SAPT. In this article, we discuss the current evidence for different therapeutic frameworks for integration sessions when serotonergic psychedelics and entactogens are used as adjuncts to psychotherapy...
December 26, 2023: Clinical Psychology & Psychotherapy
https://read.qxmd.com/read/38117108/-psychedelic-assisted-psychotherapy-in-palliative-medicine
#22
JOURNAL ARTICLE
Amandine Schaller, Géraldine Bourquin, Indira Amorim Araujo, Michael Ljuslin
Depression, anxiety and existential distress associated with terminal illness have a major impact on quality of life among palliative care patients. Psychedelics are emerging as catalysts for reflective, introspective and sometimes spiritual exploration as part of psychotherapy, with potentially rapid and long-lasting multiple beneficial effects. Psychedelic-assisted psychotherapy (PAP) combines preparation, substance intake, and integration of experiences to facilitate profound psychospiritual change. Despite methodological and administrative hurdles, interest in this innovative approach continues to grow because of its potential to offer remission where conventional approaches have shown little benefits...
December 20, 2023: Revue Médicale Suisse
https://read.qxmd.com/read/38105655/psilocybin-assisted-group-therapy-in-patients-with-cancer-diagnosed-with-a-major-depressive-disorder
#23
JOURNAL ARTICLE
Manish Agrawal, William Richards, Yvan Beaussant, Sarah Shnayder, Rezvan Ameli, Kimberly Roddy, Norma Stevens, Brian Richards, Nick Schor, Heather Honstein, Betsy Jenkins, Mark Bates, Paul Thambi
BACKGROUND: Depression is common in patients with cancer and is associated with lower treatment adherence and reduced quality of life. Antidepressants and psychotherapy have limited success in improving depression among patients with cancer. This study explored the safety, feasibility, and efficacy of psilocybin-assisted therapy in patients with cancer and major depressive disorder. METHODS: This phase 2, open-label trial enrolled patients with curable and noncurable cancer and major depressive disorder at a single community oncology practice site...
December 18, 2023: Cancer
https://read.qxmd.com/read/38101439/treatment-with-psychedelics-is-psychotherapy-beyond-reductionism
#24
REVIEW
Gerhard Gründer, Manuela Brand, Lea J Mertens, Henrik Jungaberle, Laura Kärtner, Dennis J Scharf, Moritz Spangemacher, Max Wolff
Treatment of psychiatric disorders with psychedelic substances represents one of the most promising current treatment approaches in psychiatry. Since its inception in the 1950s, therapy with psychedelics has been conceptualised as psychedelic-assisted psychotherapy-ie, a form of psychotherapy that uses the profound biological effects of this class of substances as a catalyst for changing thinking, emotions, and behaviour. In this view, the psychotherapy component of the treatment is considered as being of the utmost importance for both the safety and efficacy of the therapy...
December 12, 2023: Lancet Psychiatry
https://read.qxmd.com/read/38055270/single-dose-synthetic-psilocybin-with-psychotherapy-for-treatment-resistant-bipolar-type-ii-major-depressive-episodes-a-nonrandomized-controlled-trial
#25
JOURNAL ARTICLE
Scott T Aaronson, Andrew van der Vaart, Tammy Miller, Jeffrey LaPratt, Kimberly Swartz, Audrey Shoultz, Margo Lauterbach, Harold A Sackeim, Trisha Suppes
IMPORTANCE: Bipolar II disorder (BDII) is a debilitating condition frequently associated with difficult-to-treat depressive episodes. Psilocybin has evidence for rapid-acting antidepressant effects but has not been investigated in bipolar depression. OBJECTIVE: To establish the safety and efficacy of psilocybin in patients with BDII in a current depressive episode. DESIGN, SETTING, AND PARTICIPANTS: This was a 12-week, open-label nonrandomized controlled trial conducted at Sheppard Pratt Hospital...
December 6, 2023: JAMA Psychiatry
https://read.qxmd.com/read/38047669/ketamine-assisted-psychodynamic-psychotherapy
#26
JOURNAL ARTICLE
John G Cottone
This case report details the treatment of a longtime psychodynamic psychotherapy patient, with a particular focus on a ketamine-assisted psychotherapy (KAP) session, and how the progress achieved during this session compares with the literature on KAP. The patient is a 54-year-old woman with a history of multiple traumas, including sexual assault and life-threatening physical injuries, as well as a recent diagnosis of primary lateral sclerosis (PLS). For most of her life, she relied on extreme idealization of important people in her life as her primary defense mechanism, helping her to maintain physical and psychological survival...
December 2023: Psychodynamic Psychiatry
https://read.qxmd.com/read/38043078/classical-psychedelics-in-psychiatry-renaissance-of-interest-and-therapeutic-perspectives
#27
REVIEW
Askaniusz Jachimowski, Krzysztof Kucia
Substances that change the states of consciousness have been used in the therapeutics of traditional cultures for hundreds of years. In the Western cultural circle, scientific curiosity and hope for a breakthrough in the treatment of various mental disorders constituted the basis of the first wave of research on humans with the use of psychedelics. After synthesizing LSD, psychedelic substances aroused intense but short-term interest among mental health specialists at the beginning of the second half of the 20th century...
June 30, 2023: Psychiatria Polska
https://read.qxmd.com/read/38018944/-interest-and-mechanisms-of-action-of-ketamine-in-alcohol-addiction-%C3%A2-a-review-of-clinical-and-preclinical-studies
#28
JOURNAL ARTICLE
Fahd Hilal, Jérôme Jeanblanc, Mickaël Naassila
Alcohol Use Disorder (AUD) is a psychiatric condition characterized by chronic and excessive drinking despite negative consequences on overall health and social or occupational functioning. There are currently limited treatment options available for AUD, and the effects size and the response rates to these treatments are often low to moderate. The World Health Organization has identified the development of medications to treat AUD as one of its 24 priorities. This past decade was marked by a renewed interest in psychedelic use in psychiatry...
2023: Biologie Aujourd'hui
https://read.qxmd.com/read/38009477/treating-posttraumatic-stress-disorder-and-alcohol-use-disorder-comorbidity-current-pharmacological-therapies-and-the-future-of-mdma-integrated-psychotherapy
#29
REVIEW
Brian J Gully, Erica Eaton, Christy Capone, Carolina L Haass-Koffler
Posttraumatic stress disorder (PTSD) and alcohol use disorder (AUD) frequently co-occur in patients who have experienced trauma. This comorbidity leads to a vicious cycle where PTSD symptoms beget heavy drinking and vice versa. There are no FDA-approved medications to treat PTSD-AUD; therefore, individuals suffering from this comorbidity are treated with medication approved to treat the disorders separately or with off-label pharmacological interventions. However, these medications are limited in their efficacy for treating PTSD-AUD comorbidity...
November 27, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/37948338/ancient-medicine-for-a-modern-disease-traditional-amazonian-medicine-to-treat-substance-use-disorders
#30
REVIEW
Fernando Mendive, Cecile Giovannetti, Sara García Arce
Background: There exists an underexploited opportunity to develop innovative therapeutic approaches to SUDs based upon the complementarity between modern and traditional health systems. Objectives: Illustrate the feasibility and potentiality of such an approach through the comprehensive description of Takiwasi Center's treatment model and program, where health concepts and practices from traditional Amazonian medicine work synergistically with modern psychotherapy and medicine in an intercultural dialog to assist in the rehabilitation of people suffering from SUDs...
November 2, 2023: American Journal of Drug and Alcohol Abuse
https://read.qxmd.com/read/37942467/when-the-trial-ends-the-case-for-post-trial-provisions-in-clinical-psychedelic-research
#31
JOURNAL ARTICLE
Edward Jacobs, Ashleigh Murphy-Beiner, Ian Rouiller, David Nutt, Meg J Spriggs
The ethical value-and to some scholars, necessity-of providing trial patients with post-trial access (PTA) to an investigational drug has been subject to significant attention in the field of research ethics. Although no consensus has emerged, it seems clear that, in some trial contexts, various factors make PTA particularly appropriate. We outline the atypical aspects of psychedelic clinical trials that support the case for introducing the provision of PTA within research in this field, including the broader legal status of psychedelics, the nature of the researcher-therapist/participant relationship, and the extended time-frame of the full therapeutic process...
2024: Neuroethics
https://read.qxmd.com/read/37935915/can-research-on-entactogens-contribute-to-a-deeper-understanding-of-human-sexuality
#32
REVIEW
Justyna Holka-Pokorska
In recent years, scientific research into the therapeutic potential of psychedelic compounds has experienced a resurgence of interest. New studies have shown promising results, supporting the use of psychedelic drugs in treating various psychiatric disorders, including treatment-resistant depression, post-traumatic stress disorder, and even alcohol addiction. The FDA has recognized 3,4-methylenedioxymethamphetamine (MDMA) as a breakthrough therapy to treat symptoms of post-traumatic stress disorder. At the same time, interviews with recreational MDMA users have documented experiences of emotional intimacy while using MDMA, often without the desire for penetrative sex...
November 8, 2023: Pharmacological Reports: PR
https://read.qxmd.com/read/37921118/mystical-and-affective-aspects-of-psychedelic-use-in-a-naturalistic-setting-a-linguistic-analysis-of-online-experience-reports
#33
JOURNAL ARTICLE
Marija Franka Žuljević, Antonija Mijatović, Stjepan Ljudevit Marušić, Gunnar Kudrjavets, Ivan Buljan, Darko Hren
Analyzing online retrospective experience reports of psychedelic use can provide valuable insight into their acute subjective effects. Such reports are unexplored in relation to mystical states, which are thought to be a therapeutic mechanism within psychedelic-assisted psychotherapy. We created a set of words that, when encountered in an experience report, indicate the occurrence of mystical elements within the experience. We used the Shroomery.org website to retrieve 7317 publicly available retrospective psychedelic experience reports of psychedelic use, primarily of psilocybin, and have a designated experience intensity level self-assessed by the text authors during submission of the report...
November 3, 2023: Journal of Psychoactive Drugs
https://read.qxmd.com/read/37904908/back-from-the-rabbit-hole-theoretical-considerations-and-practical-guidelines-on-psychedelic-integration-for-mental-health-specialists
#34
REVIEW
Jakub Greń, Filip Tylš, Michał Lasocik, Csaba Kiraly
The growing interest in and prevalence of the use of psychedelics, as well as the potential benefits and negative consequences associated with psychedelic experiences, create a need for mental health specialists to be able to provide adequate and effective intervention regarding the content and consequences of these experiences, that is, psychedelic integration. At the same time, current graduate training in psychiatry, psychology, psychotherapy, counseling, etc., fails to adequately prepare professionals for such interventions...
2023: Frontiers in Psychology
https://read.qxmd.com/read/37869510/the-ego-in-psychedelic-drug-action-ego-defenses-ego-boundaries-and-the-therapeutic-role-of-regression
#35
REVIEW
Tobias Buchborn, Hannes S Kettner, Laura Kärtner, Marcus W Meinhardt
The ego is one of the most central psychological constructs in psychedelic research and a key factor in psychotherapy, including psychedelic-assisted forms of psychotherapy. Despite its centrality, the ego-construct remains ambiguous in the psychedelic literature. Therefore, we here review the theoretical background of the ego-construct with focus on its psychodynamic conceptualization. We discuss major functions of the ego including ego boundaries, defenses, and synthesis, and evaluate the role of the ego in psychedelic drug action...
2023: Frontiers in Neuroscience
https://read.qxmd.com/read/37844352/psilocybin-assisted-therapy-for-depression-a-systematic-review-and-meta-analysis
#36
REVIEW
Sipan Haikazian, David C J Chen-Li, Danica E Johnson, Farhan Fancy, Anastasia Levinta, M Ishrat Husain, Rodrigo B Mansur, Roger S McIntyre, Joshua D Rosenblat
The aim of this review was to determine the effect of psilocybin on depressive symptoms in patients diagnosed with life-threatening illnesses or major depressive disorder. Systematic searches were conducted to search for randomized clinical trials and open-label trials that evaluated depression symptoms after psilocybin therapy. Data was pooled using a random-effects model. The primary outcome was the standardized mean difference (SMD) in depression severity, determined by calculating the change in depression ratings from baseline to the primary endpoint in the psilocybin arm versus the control arm...
November 2023: Psychiatry Research
https://read.qxmd.com/read/37842884/acute-but-not-long-lasting-antidepressant-like-effect-of-psilocybin-in-differential-reinforcement-of-low-rate-72-schedule-in-rats
#37
JOURNAL ARTICLE
Natalia Malikowska-Racia, Maciej Koniewski, Joanna Golebiowska, Piotr Popik
BACKGROUND: In clinical studies, psychedelics including psilocybin and D-lysergic acid diethylamide (LSD) demonstrate rapid and persistent antidepressant effects. Since the effective treatment with psychedelics is usually provided with psychotherapy, it is debatable whether their prolonged efficacy can be observed in infrahuman species. Preclinical reports on psychedelics' effects most often address their acute actions, and different tests and models provide inconsistent results. The goal of this study was to examine whether the treatment with psilocybin and/or LSD would demonstrate immediate and/or sustained antidepressant-like effects in the differential reinforcement of low-rate responding (DRL) schedule in rats...
October 16, 2023: Journal of Psychopharmacology
https://read.qxmd.com/read/37840802/how-psychedelic-assisted-therapy-works-for-depression-expert-views-and-practical-implications-from-an-exploratory-delphi-study
#38
JOURNAL ARTICLE
Lauren Johansen, Paul Liknaitzky, Maja Nedeljkovic, Greg Murray
As investigations into the efficacy of psychedelic-assisted psychotherapy to treat depression continue, there is a need to study the possible mechanisms of action that may contribute to the treatment's antidepressant effects. Through a two-round Delphi design, the current study investigated experts' opinions on the psychological mechanisms of action associated with the antidepressant effects of psychedelic-assisted psychotherapy and the ways such mechanisms may be promoted through the preparation, dosing, and integration components of treatment...
2023: Frontiers in Psychiatry
https://read.qxmd.com/read/37830221/ensuring-the-affordable-becomes-accessible-lessons-from-ketamine-a-new-treatment-for-severe-depression
#39
JOURNAL ARTICLE
Anthony Rodgers, Dilara Bahceci, Christopher G Davey, Mary Lou Chatterton, Nick Glozier, Malcolm Hopwood, Colleen Loo
In this paper, the case study of ketamine as a new treatment for severe depression is used to outline the challenges of repurposing established medicines and we suggest potential solutions. The antidepressant effects of generic racemic ketamine were identified over 20 years ago, but there were insufficient incentives for commercial entities to pursue its registration, or support for non-commercial entities to fill this gap. As a result, the evaluation of generic ketamine was delayed, piecemeal, uncoordinated, and insufficient to gain approval...
October 13, 2023: Australian and New Zealand Journal of Psychiatry
https://read.qxmd.com/read/37795632/psychedelics-and-psychotherapy-is-the-whole-greater-than-the-sum-of-its-parts
#40
JOURNAL ARTICLE
Robert H Dworkin, Michael P McDermott, Sandeep M Nayak, Eric C Strain
No abstract text is available yet for this article.
October 5, 2023: Clinical Pharmacology and Therapeutics
keyword
keyword
72981
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.